San Leandro, United States
Rainier Therapeutics, founded in 2010, is at the forefront of biopharmaceutical innovation in the United States. Specializing in biotechnology, the company focuses on developing biologics to tackle significant unmet medical needs. Their hallmark initiative is a human monoclonal antibody named B-701. This pioneering product is distinguished as the most advanced FGFR3-specific antagonist in development, aimed at disrupting the activity of fibroblast growth factor receptor 3—a crucial advancement in targeted therapy for bladder cancer.
With their slogan, "Advancing Targeted Therapy for Bladder Cancer," Rainier Therapeutics demonstrates a clear focus on health and wellness innovation. In May 2018, the company secured a significant $20.00M Series B investment from leading investors including HealthCap, Sofinnova Investments, and Sectoral Asset Management, among others. This strategic backing indicates strengthening investor confidence in their scientific potential and long-term growth prospects within the industry.
